RFC and MTHFR SNPs & hENT1- dCK Expression as Prognostic Factors in ALL & hENT1- dCK Expression as Prognostic Factors in AML

50 participants · First posted Mar 2, 2011

Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies

70 participants · First posted Mar 20, 2025

Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer

5 participants · First posted Oct 4, 2021

Inactivated hepatitis A virus (HAV)（KM Biologics）

CYL-02

5,7-Dichlorokynurenic acid

C₁₀H₅Cl₂NO₃

DC2 Healthcare, LLC

United States

DCH AURIGA SINGAPORE

Singapore

DCH Auriga (Hong Kong) Limited

Hong Kong, China

Trethera Secures $5.3 Million in NIH Funding to Advance First-in-Class dCK Inhibitor TRE-515 Across Cancer and Autoimmune Indications

Trethera Secures $2.7 Million NIH Grant to Evaluate TRE-515 Combination Therapy for KRAS Inhibitor-Resistant Lung Cancer

Trethera Reports Disease Stabilization in Late-Stage ALS Patient Treated with TRE-515